

PRODUCT INFORMATION



Antide (acetate)

Item No. 31486

CAS Registry No.: 625092-10-6
Formal Name: N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N⁶-(3-pyridinylcarbonyl)-L-lysyl-N⁶-(3-pyridinylcarbonyl)-D-lysyl-L-leucyl-N⁶-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide, monoacetate

MF: C₈₂H₁₀₈ClN₁₇O₁₄ • C₂H₄O₂
FW: 1,651.3


Purity: ≥98%

UV/Vis.: λ_{max}: 226 nm

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Antide (acetate) is supplied as a solid. A stock solution may be made by dissolving the antide (acetate) in the solvent of choice, which should be purged with an inert gas. Antide (acetate) is soluble in ethanol and DMSO.

Description

Antide is a third generation gonadotropin-releasing hormone receptor (GnRHR) antagonist.¹⁻⁴ It inhibits GnRH-induced secretion of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and gonadotropin in isolated rat pituitary cells when used at concentrations ranging from 0.001 to 1,000 nM but does not induce histamine release in isolated rat mast cells (EC₅₀ = >300 μg/ml).^{1,3} Antide (250 μg/kg, i.v.) reduces serum LH and FSH levels in orchidectomized cynomolgus monkeys.² It inhibits ovulation in rats when administered at a dose of 2 μg/animal.³ Antide (10 μg/animal, s.c.) reduces the intensity and duration of catalepsy induced by haloperidol (Item No. 12014) in rats.⁴

References

1. Danforth, D.R., Williams, R.F., Gordon, K., *et al.* Inhibition of pituitary gonadotropin secretion by the gonadotropin-releasing hormone antagonist antide. I. *In vitro* studies on mechanism of action. *Endocrinology* **128**(4), 2036-2040 (1991).
2. Weinbauer, G.F. and Nieschlag, E. Comparison of the antigonadotropic activity of three GnRH antagonists (Nal-Glu, Antide and Cetrorelix) in a non-human primate model (*Macaca fascicularis*). *Andrologia* **25**(3), 141-147 (1993).
3. Flouret, G., Arnold, Z.S., Majewski, T., *et al.* Antioviulatory antagonists of LHRH related to antide. *J. Pept. Sci.* **1**(2), 89-108 (1995).
4. Umathe, S.N., Wanjari, M.M., Manna, S.S.S., *et al.* A possible participation of gonadotropin-releasing hormone in the neuroleptic and cataleptic effect of haloperidol. *Neuropeptides* **43**(3), 251-257 (2009).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/26/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM